- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03510338
Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products
A Pharmacoscintigraphic Clinical Study to Evaluate a Biphasic Release Sildenafil Formulation (With Immediate and Sustained Release Components) Compared to a Marketed Sildenafil Product in Fed and Fasted States
The study will assess a new biphasic release sildenafil formulation (N4S001), developed by N4 Pharma. The N4S001 tablet contains a total of 100 mg sildenafil.
The N4S001 tablet is designed to provide a faster onset of release and a longer therapeutic window compared to currently marketed sildenafil products.
This is a single centre, open-label, four-arm crossover study in up to 12 healthy male volunteers.
The following treatments will be dosed:
Assessment Visit 1: N4S001 tablet containing 100 mg sildenafil (fasted)
Assessment Visit 2: N4S001 tablet containing 100 mg sildenafil (fed)
Assessment Visit 3: Viagra film-coated tablet containing 50 mg sildenafil (fasted)
Assessment Visit 4: Viagra film-coated tablet containing 50 mg sildenafil (fed)
The immediate release layer of each N4S001 tablet will be radiolabelled to contain 4 MBq (megabecquerel) 99mTc at time of dose.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Glasgow, United Kingdom, G4 0SF
- BDD Pharma Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male
- Aged between 18 and 65 years inclusive
- BMI between 18 and 30 kg/m2 inclusive
- Body weight ≥50 kg
- Understands and is willing, able and likely to comply with all study procedures and restrictions
- Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent (signed and dated) obtained before any trial related activities
- Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination
Exclusion Criteria:
- Current or recurrent disease that, in the opinion of the physician responsible, could affect the study conduct or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure).
- Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures.
- A history of current or relevant previous non self-limiting gastrointestinal disorders.
- Currently suffering from disease known to impact gastric emptying, e.g. migraine, Type 1 or Type 2 diabetes mellitus.
- Currently suffering from any oromucosal condition (e.g. salivary gland disorders, xerostomia, aphthous ulcers) or recent oral surgery that in the opinion of the physician responsible could interfere with the study objectives.
- Currently or previously suffering from non-arteritic anterior ischaemic optic neuropathy (NAION).
- Known hereditary degenerative retinal disorders such as retinitis pigmentosa.
- Hypotension (blood pressure <90/50 mmHg).
- Recent history of stroke or myocardial infarction.
- Laboratory screening results that suggest an abnormal liver and/or renal function.
- Subject has a screening QTc value of greater than or equal to 450 msec or an ECG that is not suitable for QTc measurements (e.g. poorly defined termination of the T-wave). The ECG taken at screening must be considered not clinically significant by the Investigator/ study physician.
- As a result of a physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
- Subject has taken prescribed medication within 14 days prior to the first assessment visit which, in the opinion of the physician responsible, will interfere with the study procedures or compromise safety. Subjects will be withdrawn from subsequent study days if they commence taking prescribed medication during the study period which, in the opinion of the physician responsible, will interfere with the study procedures or compromise safety.
- Subject has taken over-the-counter (OTC) medication within 48 hours prior to the first assessment visit. This includes the use of vitamins and natural or herbal remedies. Subjects who have taken OTC medication may still be entered into the study if, in the opinion of the physician responsible, the medication will not interfere with the study procedures or compromise safety.
- Concomitant use of other phosphodiesterase 5 (PDE5) inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil (REVATIO), or other treatments for erectile dysfunction.
- Concomitant use of antihypertensive medications (e.g. diuretics, angiotensin converting enzyme (ACE) inhibitors etc).
- Concomitant use of nitrate medications.
- Recent history (within the last year) of alcohol or other substance abuse.
- Subject has an average weekly alcohol intake of greater than 21 units.
- Subject has positive urine drugs of abuse test at screening.
- Subject has a positive breath alcohol test at screening.
- Subject has recently discontinued smoking (less than 3 months).
- Subject is currently a smoker or user of nicotine-containing products.
- Subject has a positive urine cotinine test at screening.
- Subject has a history of allergy to sildenafil, to any component of the dosage form, or any other allergy, which in the opinion of the physician responsible, contraindicates their participation.
- Has an allergy to any of the contents of the standardised meals.
- Subject is vegetarian.
- Subject is lactose intolerant.
- Participation in another clinical study (inclusive of final post-study examination) or receipt of an investigational drug within the 12 weeks before first screening visit.
- Previous participation in this study.
- Subject whose participation in this study will result in participation in more than four studies over a twelve month period.
- An employee of the sponsor, client or study site or members of their immediate family.
- Subjects for whom participation in this study will exceed the limits of total radiation exposure allowed in the previous twelve month period (5 mSv), or will exceed 10 mSv over the previous three year period.
- Subjects who are intending to father a child in the 3 months following the study or are unwilling to abstain from sexual intercourse with pregnant or lactating women.
- Subjects who are unwilling to use a condom/spermicide in addition to having their female partner use another form of contraception such as an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation if the woman could become pregnant from the time of the assessment visit until 3 months following the study.
- Subject has donated blood or experienced significant blood loss within 3 months of screening and for the duration of the study.
- Difficulty accessing forearm veins for cannulation or blood sampling.
- Subject has any non-removable metal objects such as metal plates, screws etc in their chest or abdominal area, which in the opinion of the investigator, could affect the study conduct.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sublingual sildenafil (fasted)
Subjects receive a single dose of 100 mg sildenafil
|
100 mg biphasic sildenafil tablet
Other Names:
|
Active Comparator: Oral sildenafil (fed)
Subjects receive a single dose of 50 mg sildenafil (Viagra)
|
50 mg oral sildenafil (Viagra)
Other Names:
|
Experimental: Sublingual sildenafil (fed)
Subjects receive a single dose of 100 mg sildenafil
|
100 mg biphasic sildenafil tablet
Other Names:
|
Active Comparator: Oral comparator (fasted)
Subjects receive a single dose of 50 mg sildenafil (Viagra)
|
50 mg oral sildenafil (Viagra)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sildenafil plasma concentrations
Time Frame: 24 hours
|
Measure sildenafil and its main metabolite in plasma and compare pharmacokinetic profiles with that of a marketed sildenafil product in fed and fasted states
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extent of dispersion
Time Frame: 1 hour
|
Quantification of extent of dispersion of the immediate release portion of the radiolabelled N4S001 tablet in the oral cavity using gamma scintigraphy
|
1 hour
|
Visualisation of kinetics
Time Frame: 1 hour
|
Quantification the kinetics in the oral cavity of the immediate release portion of the radiolabelled N4S001 tablet using gamma scintigraphy
|
1 hour
|
Change in oral examination findings post-dose
Time Frame: 1 hour
|
Assess changes in the oral cavity following dosing of the N4S001 tablet
|
1 hour
|
Blood pressure
Time Frame: 24 hours
|
Systolic & diastolic measurements will be used to assess the effects of the N4S001 tablet compared with the marketed sildenafil product
|
24 hours
|
Heart Rate
Time Frame: 24 hours
|
Measurements will be used to assess the effects of the N4S001 tablet compared with the marketed sildenafil product
|
24 hours
|
Questionnaire
Time Frame: 1 hour
|
Assessment of taste acceptability using a 7-point categorical scale
|
1 hour
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Howard NE Stevens, FRPharmS, BDD Pharma Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BC230
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on Sublingual sildenafil
-
iX Biopharma Ltd.Linear Clinical ResearchCompletedErectile DysfunctionAustralia
-
Laboratório Teuto Brasileiro S/AUnknown
-
Medical University of LodzUnknownAllergic Rhinitis | Bronchial AsthmaPoland
-
Stallergenes GreerCompletedPrimary DiseaseFrance, Italy, Spain
-
Stallergenes GreerCompletedAllergic Rhinitis Due to Grass PollensUnited States
-
Bispebjerg HospitalLund University; University of Copenhagen; ALK-Abelló A/SCompletedThe Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma (VITAL)Allergic Asthma Due to Dermatophagoides PteronyssinusDenmark
-
ALK-Abelló A/SActive, not recruitingAllergic Rhinitis Due to Dermatophagoides Farinae | Allergic Rhinitis Due to Dermatophagoides Pteronyssinus | Allergic Rhinitis Due to House Dust MiteSpain, Russian Federation, United States, Poland, Bulgaria, Canada, France, Germany, Lithuania, Slovakia, Ukraine
-
Inmunotek S.L.CompletedRhinitis | RhinoconjunctivitisSpain
-
HAL AllergyCompletedBirch Pollen Allergy | Seasonal Rhinitis and/or RhinoconjunctivitisGermany
-
Zagazig UniversityNot yet recruitingAllergic Rhinitis